L
Luis Paz-Ares
Researcher at University of Seville
Publications - 19
Citations - 954
Luis Paz-Ares is an academic researcher from University of Seville. The author has contributed to research in topics: Lung cancer & Ramucirumab. The author has an hindex of 9, co-authored 19 publications receiving 797 citations. Previous affiliations of Luis Paz-Ares include Complutense University of Madrid & University of Zaragoza.
Papers
More filters
Journal ArticleDOI
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
M. Cobo,Dolores Isla,Bartomeu Massuti,Ana Montes,Jose Miguel Sanchez,Mariano Provencio,Nuria Viñolas,Luis Paz-Ares,Guillermo Lopez-Vivanco,Miguel Angel Muñoz,Enriqueta Felip,Vicente Alberola,Carlos Camps,Manuel Domine,Jose Javier Sanchez,Maria Sanchez-Ronco,K. D. Danenberg,Miquel Taron,David R. Gandara,Rafael Rosell +19 more
TL;DR: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin, and a multibiomarker profile predictive of patient outcome is refined.
Journal ArticleDOI
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Roy S. Herbst,Hendrik-Tobias Arkenau,Hendrik-Tobias Arkenau,Rafael Santana-Davila,Emiliano Calvo,Luis Paz-Ares,Philippe A. Cassier,Johanna C. Bendell,Nicolas Penel,Matthew G Krebs,Juan Martin-Liberal,Nicolas Isambert,Andres O. Soriano,Martin Wermke,Jennifer L. Cultrera,Ling Gao,Ryan C. Widau,Gu Mi,Jin Jin,David Ferry,Charles S. Fuchs,Daniel P. Petrylak,Ian Chau +22 more
TL;DR: The primary endpoint was the safety and tolerability of ramucirumab in combination with pembrolizumab assessed by the incidence of adverse events in both phase 1a and 1b and as dose-limiting toxicities during phase 1b.
Journal ArticleDOI
Clinicopathologic Features of Advanced Squamous NSCLC
Mark A. Socinski,Coleman K. Obasaju,David R. Gandara,Fred R. Hirsch,Philip Bonomi,Paul A. Bunn,Edward S. Kim,Corey J. Langer,Ronald B. Natale,Silvia Novello,Luis Paz-Ares,Maurice Pérol,Martin Reck,Suresh S. Ramalingam,Craig H. Reynolds,David R. Spigel,Thomas E. Stinchcombe,Heather A. Wakelee,Carlos Mayo,Nick Thatcher +19 more
TL;DR: Some of the key clinicopathologic features of squamous cell lung cancer are reviewed to optimally address many of the unique therapeutic challenges of this disease and are likely to be central to ultimately improving outcomes for patients with squamous NSCLC.
Journal ArticleDOI
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
Luis Paz-Ares,Beatrix Bálint,Richard H. de Boer,Jan P. van Meerbeeck,Rafal Wierzbicki,Paul de Souza,Francesco Galimi,Vincent Haddad,Tony Sabin,Y. J. Hei,Yang Pan,Susan Cottrell,Cheng-Pang Hsu,Rodryg Ramlau +13 more
TL;DR: Although well tolerated, the addition of conatumumab to PC did not improve outcomes in unselected patients with previously untreated advanced NSCLC.
Journal ArticleDOI
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Martin Reck,Luis Paz-Ares,Paolo Bidoli,Federico Cappuzzo,Shaker R. Dakhil,Denis Moro-Sibilot,Hossein Borghaei,Melissa Lynne Johnson,Robert M. Jotte,Nathan A. Pennell,Frances A. Shepherd,Anne Tsao,Michael Thomas,Gebra Cuyun Carter,Faye W. Chan-Diehl,Ekaterine Alexandris,Pablo Lee,Annamaria Zimmermann,Andreas Sashegyi,Maurice Pérol +19 more
TL;DR: The benefit/risk profile for refractory patients suggests that ramucirumab plus docetaxel is an appropriate treatment option even in this difficult-to-treat population.